Ascletis is taking a low and slow approach to oral GLP-1 dose titration in a phase 2a test after getting a look at clinical ...

Zurich-based startup Veraxa Biotech has reached a deal to merge with special purpose acquisition company (SPAC) Voyager, ...

Boehringer Ingelheim has slipped another piece of its oncology R&D strategy into place, partnering with Tessellate Bio on a synthetic lethal program in a deal worth more than 500 million euros ($570 ...

Thermo Fisher Scientific reported better-than-expected profit and revenue for the first quarter on Wednesday, helped by ...

This biotech company is a standout in its sector, with impressive upside potential. Here’s why we’re watching Halozyme Therapeutics (NASDAQ: HALO).